CD47’s long goodbye
Despite magrolimab’s latest flop, efforts to target CD47 continue.
Caribou aims to set itself apart from the allogeneic Car-T herd
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
KRAS and conjugates remain hot
The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.
GSK’s Blenrep Dreamm remains alive
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
